Navigation Links
New Phase IV Clinical Study Indicates LidoSite Provides,Rheumatology Patients Superior Pain Relief

FAIR LAWN, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), today announced results from a new phase IV "Open Label" clinical study demonstrating that LidoSite, the first FDA approved active patch for dermal analgesia, provided better pain relief to more than 73 percent of patients receiving injections of hyaluronic acid during treatment for osteoarthritis than usual topical analgesics.

"Treatment can be very painful, requiring multiple injections into sensitive joints, with many patients having a difficult time with this pain, leading some to avoid regular treatment," said Dr. Evan Liebowitz, a rheumatologist affiliated with Prospect Medical Office in Midland Park, NJ and Valley Hospital in Ridgewood, NJ. "Patients who avoid regular treatments for rheumatoid arthritis and osteoarthritis risk further loss of articular cartilage in the knee."

The study, involving six study sites and 14 physicians, followed 63 patients over the course of two routine injections of hyaluronic acid for the treatment of osteoarthritis.

During the first treatment, patients either received no local anesthesia or an alternate local anesthesia prior to cannulation or needle puncture. During the second treatment, patients received the LidoSite system, comprised of the LidoSite Patch and the LidoSite Controller. In the study more than 73 percent preferred LidoSite to the treatment used during their first visit. Additionally, the majority of rheumatology physicians surveyed were satisfied with LidoSite, compared to other available treatment options, such as ethyl chloride, lidocaine injections or fluormethane spray.

"This initial study demonstrates the acceptability among patients and rheumatologists for using LidoSite as an effective treatment regime for needle pain for the multiple injections arthritis requires, as well as its potential availability in the doctor's office setting."
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data Solutions ... new website design . The main website, along with ... the company,s new services and content relevant to the ... new streamlined design, viewers can now better understand how ... care practices and create a more visible platform about ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ –  Royal ... AEX: PHIA) today announced its ... of Cardiology (ESC) Congress 2014 , where ... of its cardiology solutions serving clinicians and patients ... and diagnosis, to treatment, recovery ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2PMDS Announces New Website 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 3Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 4Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 5
... 21, 2007 - Antigenics Inc.,(NASDAQ: AGEN) today ... 3 investigational therapeutic cancer vaccine,Oncophage(R) (vitespen). The ... data collection, showed that in a substantial,subset ... risk for disease,recurrence, Oncophage demonstrated a clinically ...
... FDA for long-term,maintenance treatment of COPD bronchoconstriction; ... lung function,comparable to dry powder formoterol, enhanced ... -- , NAPA, CA (May 20, 2007) ... the American Thoracic Society (ATS),demonstrate that Perforomist™ ...
Cached Medicine Technology:Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 2Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 3Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
(Date:8/29/2014)... August 29, 2014 According to new research ... Not Peer Pressure, Key to Prescription Drug Misuse Among Young ... focus for 18-29 year olds when it comes to prescription ... for this age group the real problem which influences misuse ... associations and recreational use of them to have fun with ...
(Date:8/29/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Glass microfiber including its ... explores global and China’s top manufacturers of Glass ... and market share etc. , The report further ...
(Date:8/29/2014)... Mirada, CA (PRWEB) August 29, 2014 ... which will give patients the convenience of visiting ... with Healthpointe doctors through telemedicine. , Healthpointe doctors are ... calls (or audio). If necessary, the doctor can even ... assessed the patient’s condition, he or she can prescribe ...
(Date:8/29/2014)... 2014 Healthpointe is pleased to ... Therapy students via Clinical Rotations. Physical ... shadowing Healthpointe providers and specialists throughout their daily ... clinical experience and learn professional preparation. ... insight into several patient care techniques and expand ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Healthpointe ... J. Chuang, has joined their practice. Dr. Chuang garners ... and specializes in minimally-invasive arthroscopic and reconstructive treatments of ... care for patients with general and sports-related orthopedic needs. ... in the medical field. As an Orange County native, ...
Breaking Medicine News(10 mins):Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If you,re ... recall due to salmonella contamination has probably made you refrain from ... now some time has passed, and you,re starting to crave an ... languishing in your fridge or are you inviting a bout of ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- ... caloric overindulgence can be easily worked off at the gym, ... a month,s worth of unhealthy living changes physiology, making piled-on ... [over-eating] can have later long-term effects," said study co-author Dr. ...
... in seven patients experience more pain, physical and emotional problems ... quarter have less vitality. Those are the key findings of ... by the British Journal of Surgery . ... men with an average age of 54, who had undergone ...
... TUESDAY, Aug. 24 (HealthDay News) -- A new study finds ... the glucose-lowering diabetes drugs Avandia and Actos are about the ... studies that found that the risk was elevated for Avandia ... in line with some other previous studies, further muddying the ...
... room waiting times could be cut by over one third ... a new approach to the triage process of sorting ... in the International Journal of Six Sigma and Competitive ... University in Zarqa, Jordan and colleagues have turned to a ...
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay ... the herpes virus should not worry that their use ... than 1 percent of women develop herpes simplex during ... during pregnancy of antiviral drugs such as acyclovir (Zovirax), ...
Cached Medicine News:Health News:Are The Eggs in Your Fridge Safe to Eat? 2Health News:Are The Eggs in Your Fridge Safe to Eat? 3Health News:Are The Eggs in Your Fridge Safe to Eat? 4Health News:Short-Term Overeating Could Make Long-Term Weight Loss Tougher 2Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 3Health News:Engineering shorter wait times in the ER 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 3
... clinical image management. Mediscan is an ... system derived from extensive experience with ... capture, organize, and distribute high quality ... minimum effort. Can be connected to ...
... OxyLite represents a major breakthrough in the ... Based on the principle of oxygen quenching ... quantitative monitoring of regional pO2 in tissue ... been shown to overcome many of the ...
Derrico Perforator Drill and Enlarging Burr...
Hough Hough Burr-Saw for Crurotomy, 1 mm, ISO-No. 010....
Medicine Products: